Navigation Links
High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April: Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic fatty liver disease (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA a naturally occurring bile acid, historically used to treat gallstones is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment liver biopsies from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™
2. Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine
3. Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
4. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
5. California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
8. Progenitor Cell Therapy Expands Manufacturing Operations
9. Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
10. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries
11. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... have been lionized in the press and academic circles ... performance and stellar financial results. While these leaders and ... management philosophies they represent and the practices they espouse ... and yank approach to pruning the bottom 10% of ...
... and Underwriters Laboratories have announced they will work ... tests for telecommunications suppliers. The tests cover ... transportation vibration, heat, humidity, and altitude. , , ... will provide customers of both companies access to ...
... It's easy to be fooled by first impressions. And I have ... to profile Confoti in the January 2002 issue of DEMOletter, I ... sold over the Internet. Dot-com businesses were imploding left ... supply site wouldn't be around for long. , ,I couldn't ...
Cached Biology Technology:Seven leadership lessons of Next Generation Companies 2Seven leadership lessons of Next Generation Companies 3Confoti: Revisiting a dotcom business model 2Confoti: Revisiting a dotcom business model 3Confoti: Revisiting a dotcom business model 4Confoti: Revisiting a dotcom business model 5
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the ... Food and Drug Administration (FDA) on January 30, 2009 ... walking ability in people with multiple sclerosis (MS). The ... be subject to standard review, which would provide a ...
... Edible fungus foils dangerous grapefruit-drug interactions, Journal ... Florida report that adding an edible mushroom-like fungus to ... effects that can occur when people taking certain prescription ... January 14 edition of the ACS, bi-weekly Journal ...
... A drug used to improve blood flow to the ... the risk of Alzheimer,s disease, according to a new study ... (TGen) and Arizona State University. Fasudil has been used ... in stroke patients by dilating blood vessels when blood flow ...
Cached Biology News:Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 3American Chemical Society's Weekly PressPac -- Jan. 28, 2009 4American Chemical Society's Weekly PressPac -- Jan. 28, 2009 5American Chemical Society's Weekly PressPac -- Jan. 28, 2009 6TGen and ASU researchers find drug that could reduce risk of Alzheimer's 2TGen and ASU researchers find drug that could reduce risk of Alzheimer's 3
... designed to provide a thin film-like barrier when a ... This barrier creates the proper surface tension to ... the slide. PAP Pen contains a special formulation ... can be removed, if desired, by xylene after the ...
... Signets FAST RED Chromogen System consists ... FAST RED reacts in the presence of ... minimal background noise. The FAST RED ... ,The System Contains: , , Vial ...
... F10 tubing kit provides high-pressure tubing ... system and other chromatography systems. The ... Tefzel, and orange PEEK tubing for ... basic chromatography system running at flow ...
... Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), ... TLC ≥ 90 % Cation traces: Ca ≤ ... mg/kg Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg ... ≤ 5 mg/kg Mn ≤ 5 mg/kg Na ≤ ...
Biology Products: